Rates of serious infectious events and opportunistic infections in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials

被引：0
|
作者：
Hamza, S. [1 ]
Chon, Y. [1 ]
Hooper, M. [1 ]
MacPeek, D. [2 ]
Lin, S. [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA 91320 USA
[2] Wyeth Pharmaceut, Collegeville, Philadelphia, PA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2007年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] Rates of cardiovascular events in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis treated with etanercept or placebo in clinical trials.
    Bathon, J.
    Fleischmann, R.
    Peloso, P.
    Chon, Y.
    Hooper, M.
    Lin, S-L
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S188 - S188
  • [2] ETANERCEPT RETENTION RATES IN PATIENTS WITH RHEUMATOID ARTHRITIS, ANKYLOSING SPONDYLITIS OR PSORIATIC ARTHRITIS
    Dongen, C. V.
    Kneepkens, E.
    Vogelzang, E.
    l'Ami, M.
    Krieckaert, C.
    van der Horst, I.
    Voskuyl, A.
    Nurmohamed, M.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 1145 - 1145
  • [3] Risk: Benefit Profile of Etanercept in Elderly Patients with Rheumatoid Arthritis, Ankylosing Spondylitis or Psoriatic Arthritis
    Roy Fleischmann
    Imran Iqbal
    [J]. Drugs & Aging, 2007, 24 : 239 - 254
  • [4] Risk: Benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis
    Fleischmann, Roy
    Iqbal, Imran
    [J]. DRUGS & AGING, 2007, 24 (03) : 239 - 254
  • [5] The impact of etanercept on retinal microcirculation and vascular dysfunction in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Neumann, T.
    Knoll, K.
    Betge, S.
    Jung, C.
    Otto, G.
    Wolf, G.
    Saemann, A.
    [J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2014, 73 : 12 - 12
  • [6] Biosimilar Etanercept Use in Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis: The RHUMADATA® Registry Experience
    Moura, Cristiano S.
    Choquette, Denis
    Coupal, Louis
    Bessette, Louis
    Bernatsky, Sasha
    [J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [7] Interval prolongation of etanercept in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a randomized controlled trial
    Ruwaard, J.
    Ami, M. J. L'
    Kneepkens, E. L.
    Krieckaert, C. L. M.
    Nurmohamed, M. T.
    Hooijberg, F.
    van Kuijk, A. W. R.
    van Denderen, J. C.
    Burgemeister, L.
    Rispens, T.
    Boers, M.
    Wolbink, G. J.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2023, 52 (02) : 129 - 136
  • [8] Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
    Sacchi, Viola
    Zaniolo, Orietta
    Olivieri, Ignazio
    [J]. FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2010, 11 (02) : 63 - 76
  • [9] Biosimilar Infliximab Treated-Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis in France: Characteristics and Clinical Outcomes
    Marotte, Hubert
    Mammar, Nadir
    Fautrel, Bruno
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [10] Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
    Leu, Jocelyn H.
    Adedokun, Omoniyi J.
    Gargano, Cynthia
    Hsia, Elizabeth C.
    Xu, Zhenhua
    Shankar, Gopi
    [J]. RHEUMATOLOGY, 2019, 58 (03) : 441 - 446
12345